A second phase 1 trial plans to evaluate CER-1236, a novel chimeric antigen receptor therapy, for solid tumors.

Toxicity related to the systematic delivery of IL-12, a well-known and widely researched anti-tumor cytokine, has limited its ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer On ...

Imunon has announced the alignment of the FDA with the Phase III OVATION 3 trial of IMNN-001 for ovarian cancer protocol.

The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory ...

First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer Initiation of trial sites underway for ground-breaking Phase 3 pivo ...

IMUNON (IMNN) announced that the U.S. Food and Drug Administration is aligned with the protocol for the Phase 3 pivotal trial, called OVATION ...

The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase 2 development. IMNN-001 works by instructing ...

The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer Patient enrollment in Phase 3 pivotal trial of IMNN-001 scheduled to begin in Q1 ...